Route : -
Dose/Conc.(herb) : Combination assays were performed using appropriate concentrations of P. emblica and T. bellerica extracts (4, 8, 16, 24 and 48 micrograms/mL for A549 cells, and 25, 50, 75, 100, and 200 micrograms/mL for HepG2 cells) with appropriate concentrations of doxorubicin (0.029, 0.058, 0.116, 0.174, and 0.348 micrograms/mL) or cisplatin (0.1, 0.2, 0.3, 0.4, and 0.8 micrograms/mL).
Remark : - With A549 cells, the combinations were synergistic at medium and high dose levels (IC75 and IC90) for the P. emblica/doxorubicin and P. emblica/cisplatin combinations. By contrast, the synergistic and additive effects were recorded at low and medium dose levels (IC50 and IC75) for the T. bellerica/cisplatin combination. In HepG2 cells, combinations were synergistic at low and medium dose levels (IC50 and IC75) for the P. emblica/doxorubicin combination or at a low level (IC50) for the T. bellerica/doxorubicin combination. All other combinations had antagonistic effects.
- The growth inhibitory activity of doxorubicin or cisplatin, as a single agent, may be modified by combinations of P. emblica or T. bellerica extracts and be synergistically enhanced in some cases. Depending on the combination ratio, the doses for each drug for a given degree of effect in the combination may be reduced.
